Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neuro-Ophthalmology Oculoplastics Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login

How Treatments for DR/DME are Modernizing Medical Retina

By: Christina Y. Weng, MD, MBA (Chair); Sophie J. Bakri, MD; David A. Eichenbaum, MD, FAAO; Glenn Yiu, MD, PhD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

Content Source
This continuing medical education (CME) activity captures content from a virtual roundtable discussion.

Activity Description
This supplement summarizes an in-depth discussion into the available treatment options for diabetic retinopathy (DR) and diabetic macular edema (DME), as well as the challenges faced by retina specialists and patients in the current environment of COVID-19. The faculty also reviews emerging therapies and the potential they have for longer duration and improved outcomes.

Target Audience
This certified CME activity is designed for retina specialists.

Expiration Date: Tuesday, February 28, 2023
Release Date: November 30, 2021

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Describe the pros and cons of current therapy options for diabetic eye disease
  • Articulate the challenges facing retina specialists related to the complexities of managing patients with DR and DME
  • Assess pipeline candidates under investigation for these patient populations

Accreditation and Designation Statement

This educational activity is provided by Evolve Medical Education LLC (Evolve).

Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Christina Y. Weng, MD, MBA (Chair)

Associate Professor of Ophthalmology
Baylor College of Medicine 
Houston, Texas 

Sophie J. Bakri, MD

Professor and Chair
Department of Ophthalmology
Mayo Clinic
Rochester, MN

David A. Eichenbaum, MD, FAAO

Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
Tampa, Florida

Glenn Yiu, MD, PhD

Associate Professor
University of California—Davis
Sacramento, California

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Christina Y. Weng, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Alimera Sciences, Allergan/AbbVie, DORC, Genentech, Novartis, Regeneron Pharmaceuticals, and Regenxbio.

Sophie J. Bakri, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Allergan, Alimera, Apellis, Eyepoint Pharmaceuticals, Regenexbio, Genentech, Kala Pharmaceuticals, Novartis, and Roche.

David A. Eichenbaum, MD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, EyePoint Pharmaceuticals, Genentech, Gyroscope, IvericBio, Kodiak, Notal Vision, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, AsclepiX, Bayer, Chengdu, Gemini, Genentech, Gyroscope, lonis, lvericBio, Kodiak, Mylan, NGM, Novartis, Opthea, and Regeneron Pharmaceuticals. Speaker’s Bureau: Allergan, Bayer, DORC, EyePoint Pharmaceuticals, Genentech, and Novartis.

Glenn Yiu, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Clearside Biomedical, Genentech, Iridex, Intergalactic Therapeutics, NGM Biopharmaceutical, Regeneron, Topcon.

The Evolve staff and planners have no financial relationships with commercial interests. Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Retina Today, or Genentech.

Begin Course